---
title: 'Wiskott-Aldrich Syndrome: A study on 577 patients defining the genotype as
  a predictive biomarker for disease severity'
date: '2024-04-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38579284/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240406181030&v=2.18.0.post9+e462414
source: Blood
description: WAS is a multifaceted monogenic disorder with a broad disease spectrum
  and variable disease severity and a variety of treatment options including allogeneic
  hematopoietic stem cell transplantation (HSCT) and gene therapy (GT). No reliable
  biomarker exists to predict disease course and outcome for individual patients.
  A total of 577 patients with a WAS variant from 26 countries and a median follow-up
  of 8.9 years (0.3-71.1), totaling 6118 patient-years, were included in this ...
disable_comments: true
---
WAS is a multifaceted monogenic disorder with a broad disease spectrum and variable disease severity and a variety of treatment options including allogeneic hematopoietic stem cell transplantation (HSCT) and gene therapy (GT). No reliable biomarker exists to predict disease course and outcome for individual patients. A total of 577 patients with a WAS variant from 26 countries and a median follow-up of 8.9 years (0.3-71.1), totaling 6118 patient-years, were included in this ...